Cascade Pharma key facts
- Developer of nuclear receptor drugs intended to provide new therapies for chronic liver diseases.
- It has raised $217.6M; the latest was Later Stage VC ($71.9M) in Feb 2026.
- Notable investors include Puhua Capital, Lapam Capital, CAS Investment Management, Shanghai Pudong Venture Capital, Shanghai Lingang Economic Development — 24 tracked in total.
- Status: Privately Held (backing).
Who backs Cascade Pharma
24+Membership and data by Private Market View
- ·The complete investor list: 24 names
- ·Watch Cascade Pharma: the Monday email on marks, rounds and moves
Cascade Pharma funding rounds
No funding rounds for Cascade Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Cascade Pharma investors
24 investors are on record for Cascade Pharma, including Puhua Capital, Lapam Capital, CAS Investment Management and Shanghai Pudong Venture Capital.
About Cascade Pharma
Developer of nuclear receptor drugs intended to provide new therapies for chronic liver diseases. The company develops innovative drugs targeting nuclear receptors, enabling healthcare professionals to better treat patients with metabolic liver diseases and inflammation.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2017
- Employees
- 29
- Website
- cascadepharm.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Cascade Pharma doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.